Guangzhou KingMed Diagnostics was the leading third-party independent clinical laboratory in China. On the eve of the Lunar New Year in 2020, the chairman and CEO of Guangzhou KingMed Diagnostics mobilized the whole group to respond to the outbreak of the new coronavirus from Wuhan. With the group's tremendous growth in both business and size since its initial public offering, there were growing concerns about the provision of quality customer service and the group's profitability. While the chairman and CEO was proud to see how swiftly his team had responded to the COVID-19 pandemic, he had many questions about the efficiency of the entire group's resource deployment and the consistency of performance across subsidiaries. Post COVID-19, how should Guangzhou KingMed Diagnostics adjust its transformation strategy? H. Brian Hwarng is affiliated with National University of Singapore.

【書誌情報】

ページ数：17ページ

サイズ：A4

商品番号：HBSP-W25196

発行日：2021/10/17

登録日：2022/5/16